Skip to content
Screener

CapEx at other companies

Eli Lilly logo
Eli LillyLLY
$2.93B+72.8%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$0-100%
Immunome logo
ImmunomeIMNM
$2.18M+140%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$2.34M-70.7%
uniQure logo
uniQureQURE
$472K+81.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$2K-104%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$29.3M-21.7%
Net income-$26.8M-24.7%
EPS (diluted)-$0.22+24.1%

Balance sheet

See full
Cash & equivalents$48.5M+68.1%
Total debt$3.9M+11.1%
Total equity$323.9M+21.9%
Total assets$392.0M+26.2%

Cash flow

See full
Operating cash flow-$20.7M-3.5%
Free cash flow-$34.8M-66.1%

Valuation

See full
Market cap$342.14M+25.3%
Enterprise value$297.56M+20.1%

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp

Returns & leverage

See full
Return on equity-39.5%+14.0pp
Debt / equity0.0×
Current ratio6.6×-8.5×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Perspective Therapeutics’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:34 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342512
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Other noncurrent liabilities121229
Net cash used in operating activities(52,118)(41,535)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment(21,053)(5,682)
Additions to other assets(21)(45)
Purchases of available-for-sale securities(185,952)(67,094)
Maturities of available-for-sale securities112,49271,520
Net cash used in investing activities(94,534)(1,301)

ITEM 1 - FINANCIAL STATEMENTS

FAQ

What is Perspective Therapeutics's capex?
Perspective Therapeutics (CATX) reported capex of $14.2M in Q2 2026.
How has Perspective Therapeutics's capex changed year-over-year?
Perspective Therapeutics's capex increased by 1283.5% year-over-year, from $1.03M to $14.2M.
What is the long-term trend for Perspective Therapeutics's capex?
Over 2 years (2023 to 2025), Perspective Therapeutics's capex has grown at a 244.9% compound annual growth rate (CAGR), from $1.07M to $12.75M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Ask your AI about Perspective Therapeutics's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude